Pharmaceutical industry welcomes “barrier-free access” to the internal market
Published: Friday, Mar 8th 2024, 16:20
Back to Live Feed
The pharmaceutical industry has welcomed the adoption of the negotiating mandate with the EU. The "Bilaterals III" secured barrier-free access to the EU internal market, access to skilled workers and participation in EU programs.
Stable relations with the EU are key for Switzerland's largest export industry, wrote the trade association Scienceindustries on X. And the industry association Interpharma emphasized in a press release that by entering into negotiations with the EU, the so-called Mutual Recognition Agreement (MRA) could be updated to reduce technical barriers to trade.
This is of great importance for the industry's exports and security of supply. In addition, the free movement of persons offers the pharmaceutical industry access to "urgently needed qualified specialists". This is because the national market is not large enough to meet the high demand.
Finally, Swiss participation in EU research programs would be secured in the long term, without which Switzerland would have lost its attractiveness as a research location.
©Keystone/SDA
English 
German 
French 
Spanish 
Arabic